ALNY

Alnylam Pharmaceuticals, Inc.
CAPPED RATING

Alnylam Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in developing novel therapeutics based on RNA interference, or RNAi. RNAi is a naturally occurring biological pathway within cells for regulating the expression of specific genes.

Alnylam Pharmaceuticals, Inc. (ALNY) is rated C- (2.1/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Profitability (A-); its weakest is Revisions (F). The rating has held at C- for 2 weeks.

Quantitative Factor Evaluation • Updated

Overall Rating
2.1 / 5.0
C-
Value
B-
Factor Score 3.0 / 5.0
Growth
D+
Factor Score 1.8 / 5.0
Profitability
A-
Factor Score 3.9 / 5.0
Momentum
C-
Factor Score 2.0 / 5.0
Revisions
F
Factor Score 0.0 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 8.1
EV / EBITDA 20.1
Rev Growth YoY 16.7%
Gross Margin 77.3%
Price Return 3M -30.1%
Price Return 12M -64.8%
Catalyst Signal 0.00
Market Cap $21.4B
TTM Revenue $5.0B
Price / Sales 4.3
ROE 138.1%

Historical Factor Score Progression

Held C- for 2 weeks
Date Value Growth Profitability Momentum Revisions Overall
2026-11-17 B- (3.0) D+ (1.8) A- (3.9) C- (2.0) F (0.0) C- (2.1)
2026-11-10 B- (3.0) D+ (1.8) A- (3.9) C- (2.0) F (0.0) C- (2.1)
2026-11-03 B- (3.0) D+ (1.8) A- (3.9) C- (1.9) F (0.0) C- (2.1)
2026-10-27 C+ (2.5) B (3.3) A- (4.0) C- (1.9) A+ (5.0) B (3.3)
2026-10-20 C (2.5) B (3.3) A- (4.0) C- (2.0) A+ (5.0) B (3.3)
Page 1 of 7